Lv Z - Search Results

1

OLR1 is a prognostic factor and correlated with immune infiltration in breast cancer.

Sun X, Fu X, Xu S, Qiu P, Lv Z, Cui M, Zhang Q, Xu Y. Sun X, et al. Among authors: lv z. Int Immunopharmacol. 2021 Dec;101(Pt B):108275. doi: 10.1016/j.intimp.2021.108275. Epub 2021 Oct 21. Int Immunopharmacol. 2021. PMID: 34688153

2

NKD1 down-regulation is associated with poor prognosis in breast invasive ductal carcinoma.

Lv ZD, Zhang L, Liu XP, Jin LY, Dong Q, Li FN, Wang HB, Kong B. Lv ZD, et al. Int J Clin Exp Pathol. 2015 Apr 1;8(4):4015-21. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26097589 Free PMC article.

3

Tumor-associated macrophages-mediated CXCL8 infiltration enhances breast cancer metastasis: Suppression by Danirixin.

Nie G, Cao X, Mao Y, Lv Z, Lv M, Wang Y, Wang H, Liu C. Nie G, et al. Among authors: lv m, lv z. Int Immunopharmacol. 2021 Jun;95:107153. doi: 10.1016/j.intimp.2020.107153. Epub 2021 Mar 5. Int Immunopharmacol. 2021. PMID: 33677254

4

Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy.

Tan S, Fu X, Xu S, Qiu P, Lv Z, Xu Y, Zhang Q. Tan S, et al. Among authors: lv z. Pathol Oncol Res. 2021 Dec 20;27:1609972. doi: 10.3389/pore.2021.1609972. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34987312 Free PMC article.

5

Targeting PGC1α to wrestle cancer: a compelling therapeutic opportunity.

Sun X, Liu X, Yu K, Xu S, Qiu P, Lv Z, Zhang X, Xu Y. Sun X, et al. Among authors: lv z. J Cancer Res Clin Oncol. 2022 Apr;148(4):767-774. doi: 10.1007/s00432-021-03912-z. Epub 2022 Jan 15. J Cancer Res Clin Oncol. 2022. PMID: 35032216 Review.

6

Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.

Lv ZD, Song HM, Niu ZH, Nie G, Zheng S, Xu YY, Gong W, Wang HB. Lv ZD, et al. Front Oncol. 2022 Jan 11;11:760655. doi: 10.3389/fonc.2021.760655. eCollection 2021. Front Oncol. 2022. PMID: 35087749 Free PMC article.

7

Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study.

Chen Y, Liu X, Yu K, Sun X, Xu S, Qiu P, Lv Z, Zhang X, Guo A, Xu Y. Chen Y, et al. Among authors: lv z. Ann Transl Med. 2022 Jan;10(2):93. doi: 10.21037/atm-21-6924. Ann Transl Med. 2022. PMID: 35282081 Free PMC article.

8

Predicting Pathological Complete Response in Breast Cancer After Two Cycles of Neoadjuvant Chemotherapy by Tumor Reduction Rate: A Retrospective Case-Control Study.

Yao L, Liu X, Wang M, Yu K, Xu S, Qiu P, Lv Z, Zhang X, Xu Y. Yao L, et al. Among authors: lv z. J Breast Cancer. 2023 Apr;26(2):136-151. doi: 10.4048/jbc.2023.26.e12. Epub 2023 Mar 16. J Breast Cancer. 2023. PMID: 37051647 Free PMC article.

9

Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition.

Lv ZD, Kong B, Li JG, Qu HL, Wang XG, Cao WH, Liu XY, Wang Y, Yang ZC, Xu HM, Wang HB. Lv ZD, et al. Oncol Rep. 2013 Jan;29(1):219-25. doi: 10.3892/or.2012.2111. Epub 2012 Oct 30. Oncol Rep. 2013. PMID: 23129177

10

Luminal breast cancer classification according to proliferative indices: clinicopathological characteristics and short-term survival analysis.

Sun Y, Nie G, Wei Z, Lv Z, Liu X, Wang H. Sun Y, et al. Among authors: lv z. Med Oncol. 2014 Jul;31(7):55. doi: 10.1007/s12032-014-0055-z. Epub 2014 Jun 17. Med Oncol. 2014. PMID: 24935624

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,623 results

Search Page

Filters